Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (GB:0HTB)
LSE:0HTB
Capricor Therapeutics (0HTB) Share Price & Analysis
0 Followers
0HTB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Capricor Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
36.77% Insiders
4.59% Mutual Funds
4.42% Other Institutional Investors
54.22% Public Companies and
Individual Investors
0HTB FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 15 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Feb 29, 2024. The company reported -€0.019 earnings per share for the quarter, beating the consensus estimate of -€0.084 by €0.066.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -€0.11.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 31,502,972 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -€0.019 in its last earnings report, beating expectations of -€0.084. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Among the largest hedge funds holding Capricor Therapeutics’s share is Woodline Partners LP. It holds Capricor Therapeutics’s shares valued at 4M.
---
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€24.27 (― Upside)
€24.27 (― Upside)
Blogger Sentiment
Bullish
GB:0HTB Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.99%
12-Months-Change
Fundamentals
Return on Equity
-129.63%
Trailing 12-Months
Asset Growth
17.25%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
---
0HTB Earnings Call
Q4 2024
0:00 / 0:00
---
0HTB Stock 12 Months Forecast
Average Price Target
―Capricor Therapeutics
―
Adverum Biotechnologies
―
Bioxcel Therapeutics
―
Compugen
―
Verastem
―
Best Analysts Covering 0HTB
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+17.32%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +17.32% per trade.
---